Management of combined hepatocellular and cholangiocarcinoma

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1271-1278

  Kassahun, W T ^a   Hauss, J ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; INTERFERON; RIBAVIRIN; TUMOR MARKER;

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; ECHOGRAPHY; EPIDEMIOLOGY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RADIOGRAPHY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURGICAL MORTALITY; SURGICAL RISK; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPH NODE EXCISION; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 47149109623     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01694.x     Document Type: Review

References (89)

1. Jarnagin WR, Weber S, Tickoo SK et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002 94 : 2040 6.
2. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949 25 : 647 55.
3. Koh KC, Lee H, Choi MS et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005 189 : 120 5.
4. The liver cancer study group of Japan: primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990 211 : 277 87.
5. Taguchi J, Nakashima O, Tanaka M et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 1996 11 : 758 64.
6. Goodman ZD, Ishak KG, Langloss JM et al. Combined hepatocellular- cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985 55 : 124 35.
7. Yano Y, Yamamoto J, Kosuge T et al. Combined hepatocellular and cholangiocarcinoma: clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003 33 : 283 7.
8. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocllular- cholangiocaricinoma: a clinicopathologic study. J Gastroenterol Hepatol 1998 13 : 34 40.
9. Aoki K, Takayasu K, Kawano T et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology 1993 18 : 1090 5.
10. Liu CL, Fan ST, Lo CM et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg 2003 138 : 86 90.
11. Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular- cholangiocarcinoma and cholangiocarcinoma: a clinicopathologic study. Hepatogastroenterology 2002 49 : 1487 90.
12. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinoma. J Hepatol 2004 41 : 292 8.
13. Shin CI, Lee JM, Kim SH et al. Recurrence patters of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography. J Comput Assist Tomogr 2007 31 : 109 15.
14. Zuo HQ, Yan LN, Zeng Y et al. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2007 6 : 161 5.
15. Okuda H, Shiratori K, Yamamoto M et al. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for α-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 2006 21 : 869 73.
16. Tang D, Nagano H, Nakamura M et al. Clinical and pathological features of Allen's Type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006 10 : 987 98.
17. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998 27 : 273 8.
18. Colombo M. Risk groups and preventive strategies. In : Berr F, Bruix J, Hauss J, Wands J, Wittekind Ch, eds. Malignant Liver Tumors: Basic Concepts and Clinical Management. Dordrecht : Kluwer Academic Publishers BV and Falk Foundation, 2003 : 67 74.
19. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22700 men in Taiwan. Lancet 1981 2 : 1121 33.
20. Colombo M, Kuo G, Choo Q et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989 2 : 1006 8.
21. Sun Z, Lu P, Gail MH. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology 1999 30 : 379 83.
22. Llvet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 17.
23. Bruix J, Boix L, Sala M, Llvet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004 5 : 215 9.
24. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellan and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002 17 : 401 5.
25. Kew MC. The development of hepatocellular cancer in humans. Cancer Surv 1986 5 : 719 39.
26. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002 36 : S74 83.
27. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995 15 : 64 9.
28. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988 61 : 942 56.
29. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 1999 229 : 790 800.
30. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006 13 : 537 42.
31. Davila JA, Morgan RO, Shaib Y et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004 127 : 1372 80.
32. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. The Oncologist 2004 9 : 43 57.
33. Kassahun WT, Kahn T, Wittekind Ch et al. Caroli's disease: liver resection and liver transplantation. Experience in 33 patients. Surgery 2005 138 : 888 98.
34. Lipsett PA, Pitt HA, Colombani PM et al. Choledochal cyst disease. a changing pattern of presentation. Ann Surg 1994 220 : 644.
35. Pitt HA, Dooley WC, Yeo CJ et al. Malignancies of the biliary tree. Curr Probl Surg 1995 32 : 1 90.
36. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in Children. N Engl J Med 1997 336 : 1855 9.
37. Chang MH, Shaw WY, Chen CJ et al. The Taiwan Childhood Hepatoma Study Group: hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000 284 : 3040 2.
38. Bruix J, Barrera JM, Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989 2 : 1004 6.
39. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993 328 : 1797 801.
40. Block TM, Metha AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003 22 : 5093 107.
41. Marrero JA. Hepatocllular carcinoma. Curr Opin Gastroenterol 2006 22 : 248 53.
42. Maeda T, Adachi E, Kajiyama K et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Human Pathol 1995 26 : 956 64.
43. Nakamura S, Suzuki S, Sakaguchi T et al. Surgical treatment of patients with mixed hepatocellular and cholangiocarcinoma. Cancer 1996 78 : 1671 6.
44. Uenishi T, Hirohashi K, Shuto T et al. Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology 2000 47 : 832 4.
45. De Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999 341 : 1368 78.
46. Lin J, Yan F, Hu S, Ju H. Chemiluminescent immunosensor for CA 19-9 based on antigen immobilization on a cross-linked chitosan membrane. JIM 2004 291 : 165 74.
47. Patel AH, Harnois DM, Klee GG et al. The utility of CA 19-9 in the diagnosis of cholangiocarcinoma in patients without sclerosing cholangitis. Am J Gastroenterol 2000 95 : 204 20.
48. Ramage JK, Donaghy A, Farrant JM et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995 108 : 865 9.
49. Su WC, Chan KK, Lin XZ et al. A clinical study of 130 patients with biliary tract cancers and periampullary tumors. Oncology 1996 53 : 488 93.
50. Tilghman SM, Belayew A. Transcription control of the murine albumin/alph-fetoprotein locus during development. Proc Natl Acad Sci 1982 79 : 5254 7.
51. Peng SY, Lai PL, Chu JS et al. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993 17 : 35 41.
52. Ramsey WH, Wu GY. Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis 1995 13 : 81 91.
53. Saini S. imaging of the hepatobiliary tract. N Engl J Med 1997 336 : 1889 94.
54. Araki T, Itai Y, Furui S et al. A Dynamic CT densitometry of hepatic tumors. AJR 1980 135 : 1037 43.
55. Gibson JB. Histological Typing of Tumors of the Liver, Biliary Tract, and Pancreas. Geneva, Switzerland : World Health Organization, 1978.
56. Asayama Y, Taguchi KiK, Aishima SiS et al. The mode of tumor progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-cartenin and beta cartenin. Liver 2002 22 : 43 50.
57. Honda H, Ochiai K, Adachi E et al. Hepatocellular carcinoma: correlation of CT, angiography, and histopathologic findings. Radiology 1993 189 : 857 62.
58. Honda H, Onitsuka H, Yasumori K et al. Intrahepatic peripheral cholangiocarcinoma: two-phased dynamic incremental CT and pathologic correlation. J Comput Assist Tomogr 1993 17 : 397 402.
59. Fukukura Y, Taguchi J, Nakashima O et al. Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 1997 21 : 52 8.
60. Sanada Y, Shiozaki S, Aoki H et al. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 2005 32 : 185 95.
61. Anderson Cd, Rice M, Pinson CW et al. Flourodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004 8 : 90 7.
62. Nagaoka S, Itano S, Ishibashi M et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary finding. Liver Int 2006 26 : 781 8.
63. Dusenbery D. Combined hepatocellular-cholangiocarcinoma: cytologic findings in four cases. Acta Cytol 1997 41 : 903 9.
64. Kilpatrick SE, Geisinger KR, Loggie BW, Hopkins MB. Cytomorphology of combined hepatocellular-cholangiocarcinoma in fine needle aspirates of the liver: a report of two cases. Acta Cytol 1993 37 : 943 7.
65. Wee A, Nilsson B. Combined hepatocellular-cholangiocarcinoma: diagnostic challenge in hepatic fine needle aspiration biopsy. Acta Cytol 1999 43 : 131 8.
66. Bismuth H, Majno P. Hepatobiliary surgery. J Hepatol 2000 32 : 208 24.
67. Sasaki A, Kawano K, Aramaki M et al. Clinicopathological study of mixed hepatocellular and cholangiocellular carcinoma: modes of spreading and choice of surgical treatment by reference to macroscopic type. J Surg Oncol 2001 76 : 37 46.
68. Vauthey JN, Pawlik TM, Abdalla EK et al. Is extended hepatectomy for hepatobiliary malignancy justified Ann Surg 2004 239 : 722 32.
69. Giorgio E, Gian LG, Matteo R et al. The role of lymphadenectomy for liver tumors: further consideration on the appropriateness of treatment strategy. Ann Surg 2004 239 : 2002 9.
70. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006 10 : 761 80.
71. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophagus varices. Br J Surg 1973 60 : 646 9.
72. Teh SH, Nagorney DM, Stevens SR et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007 132 : 1261 9.
73. Northup PG, Wanamaker RC, Lee VD et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 2005 242 : 244 51.
74. Malinchoc M, Kamath PS, Gordon FD et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000 31 : 864 71.
75. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 9.
76. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 2007 patients. Transplantation 2000 69 : 1633 7.
77. Shimoda M, Farmer DG, Colquhoun SD et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001 7 : 1023 33.
78. Chan AC, Lo CM, Ng IO, Fan ST. Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg 2007 2 : 143 6.
79. Llovet JM, Real MI, Montana X et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002 359 : 1734 9.
80. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999 19 : 323 8.
81. Dick EA, Taylor-Robinson SD, Thomas HC, Gedroyc WM. Ablative therapy for liver tumors. Gut 2002 50 : 733 9.
82. Onles MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004 66 : 167 79.
83. Todoroki T, Ohara K, Kawamot T et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000 46 : 581 7.
84. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil- leucoverin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994 17 : 223 6.
85. Takada T, Kato H, Matsushiro T et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994 51 : 396 400.
86. Tickoo SK, Zee SY, Obiekwe S et al. Combined hepatocellular- cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002 26 : 989 97.
87. Lee WS, Lee KW, Heo JS et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 2006 36 : 892 7.
88. Varnholt H, Asayama Y, Aishima SI et al. C-Met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. Oncol Rep 2002 9 : 35 41.
89. Wakasa T, Wakasa K, Shutou T et al. A histological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology 2007 54 : 508 13.